Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens
Authors:
- Sitthichai KanokudomSKSitthichai Kanokudom
- Jira ChansaenrojJCJira Chansaenroj
- Nungruthai SuntronwongNSNungruthai Suntronwong
- Suvichada AssawakosriSASuvichada Assawakosri
- Ritthideach YorsaengRYRitthideach Yorsaeng
- Pornjarim NilyanimitPNPornjarim Nilyanimit
- Ratchadawan AeemjindaRARatchadawan Aeemjinda
- Nongkanok KhanaratNKNongkanok Khanarat
Preprint
Abstract
Objective: To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax ™ ) given as a third (booster) dose to individuals primed with different primary vaccine regimens. Methods: Individuals primed with two doses of COVID-19 vaccines for at least 3 months were enrolled and assigned to five groups according to their primary vaccine regimens: CoronaVac, BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was performed to determine binding antibodies, neutralizing activity, and the T-cell response. Results: Overall, 215 individuals were enrolled and boosted with the Covovax ™ vaccine. The reactogenicity achieved was mild-to-moderate. Most participants elicited a high level of binding and neutralizing antibody responses against wild type and omicron variants following the booster dose. The 197 participants were classified by anti-N IgG. Of these, 141/197 (71.6%) were a seronegative population, and neutralizing activity and IFN-γ release were further monitored. A booster dose could elicit neutralizing activity to wild type and omicron variants by more than 95% and 70% inhibition at 28 days, respectively. The Covovax ™ vaccine could elicit a cell-mediated immune response. Conclusion: The protein subunit vaccine (Covovax ™ ) can be proposed as a booster dose after two different priming dose regimens. It has strong immunogenicity and good safety profiles.Keywords
This publication has 22 references indexed in Scilit:
- Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccinationInternational Journal of Infectious Diseases, 2022
- Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster doseThe Lancet, 2022
- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern AfricaNature, 2022
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature, 2021
- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralizationNature, 2021
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialThe Lancet, 2021
- Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative reviewClinical Microbiology and Infection, 2021
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialThe Lancet, 2021
- SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in miceNature Communications, 2021
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineNew England Journal of Medicine, 2020